Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aurinia Pharmaceuticals Inc (AUPH : NSDQ)

• Company Description    Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. Number of Employees: 130

• Price / Volume Information    Yesterday's Closing Price: $14.17 Daily Weekly Monthly 20 Day Moving Average: 854,276 shares Shares Outstanding: 132.97 (millions) Market Capitalization: $1,884.20 (millions) Beta: 1.53 52 Week High: $16.54 52 Week Low: $6.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.48% -1.62% 12 Week -9.28% -9.39% Year To Date -11.16% -11.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 14315 - 118 AVENUE SUITE 140 - EDMONTON,A0 T5L 4S6 CAN ph: 250-744-2487 fax: 250-744-2498 ir@auriniapharma.com http://www.auriniapharma.com

• General Corporate Information    Officers Peter Greenleaf - President; Chief Executive Officer; Director Kevin Tang - Chair of the Board Joseph Miller - Chief Financial Officer Jeffrey A. Bailey - Director David R.W. Jayne - Director Peer Information Aurinia Pharmaceuticals Inc (GSAC) Aurinia Pharmaceuticals Inc (CASIF) Aurinia Pharmaceuticals Inc (ALCD.) Aurinia Pharmaceuticals Inc (OMNN) Aurinia Pharmaceuticals Inc (CGPI.) Aurinia Pharmaceuticals Inc (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 05156V102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/11/26 Share - Related Items Shares Outstanding: 132.97 Most Recent Split Date: (:1) Beta: 1.53 Market Capitalization: $1,884.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.83 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/11/26

• Fundamental Ratios P/E Current FY Estimate: 17.12 Trailing 12 Months: 17.49 PEG Ratio: - Price Ratios Price/Book: 3.21 Price/Cash Flow: 13.98 Price / Sales: 6.66 EPS Growth vs. Year Ago Period: 188.89% vs. Previous Quarter: 13.04% Sales Growth vs. Year Ago Period: 28.81% vs. Previous Quarter: 4.96% ROE 12/31/25 - 27.47 09/30/25 - 25.19 06/30/25 - 20.06 ROA 12/31/25 - 19.61 09/30/25 - 17.25 06/30/25 - 13.81 Current Ratio 12/31/25 - 5.25 09/30/25 - 5.76 06/30/25 - 5.23 Quick Ratio 12/31/25 - 4.76 09/30/25 - 5.17 06/30/25 - 4.63 Operating Margin 12/31/25 - 39.60 09/30/25 - 33.85 06/30/25 - 27.97 Net Margin 12/31/25 - 101.46 09/30/25 - 29.28 06/30/25 - 23.31 Pre-Tax Margin 12/31/25 - 40.33 09/30/25 - 29.96 06/30/25 - 24.02 Book Value 12/31/25 - 4.41 09/30/25 - 2.77 06/30/25 - 2.55 Inventory Turnover 12/31/25 - 0.71 09/30/25 - 0.67 06/30/25 - 0.64 Debt-to-Equity 12/31/25 - 0.09 09/30/25 - 0.15 06/30/25 - 0.18 Debt-to-Capital 12/31/25 - 8.26 09/30/25 - 13.22 06/30/25 - 15.02

Powered by Zacks Investment Research ©